21/02/2014
Report no. 32/2014
Amendment to a significant contract in the subsidiary company “Mikulicz” sp. z o.o. in Świebodzice
Pursuant to §5 (1) (3) of the Regulation of the Minister of Finances of 19 February 2009 on current and periodical information provided by issuers of securities, the Management Board of EMC Instytut Medyczny S.A., reports that, on 20 February 2014, the company received annexes to the contracts concluded with the National Health Fund - the Dolnośląskie Voivodeship Branch in Wrocław (the Fund Branch) signed by the subsidiary company “Mikulicz” sp. z o.o. regarding healthcare services in the scope of hospital treatment, hospital treatment –health programmes (drug prescription programmes), palliative and hospice care, nursing and care services in terms of long-term care, outpatient specialist care, outpatient specialist care (outpatient diagnostic and cost-consuming services), psychiatric care and addiction treatment as well as primary health care for the period 1 January to 31 December 2013.
Healthcare services referred to hereinabove are provided by the subsidiary company “Mikulicz” Sp. z o.o. in Świebodzice owned by EMC Instytut Medyczny S.A.
The Issuer informed about the contracts concluded by Mikulicz sp. z o.o. with the Fund Branch concerning rendering healthcare services in 2013 in its current reports nos. 17/2013 of 05.02.2013 and 21/2013 of 13.02.2013.
As a result of signing the said annexes, the value of the contract with highest value has changed and and it currently amounts to PLN 10,734,467.40 (an increase by PLN 769.80).
The total maximum Fund Branch liability towards the subsidiary company “Mikulicz” Sp. z o.o. in Świebodzice owned by the Issuer currently amounts to PLN 14,728,191.4 (an increase by PLN 73,274.48) for healthcare services rendered in the period 1 January to 31 December 2013.
The other material terms of the contract with the highest value made public remain unchanged.
A criterion for a contract to be considered significant:
The value of contracts exceeds 10% of the Issuer’s equity capital.